Allarity Therapeutics Announces Executive Leadership Transition
29 juin 2022 16h01 HE
|
Allarity Therapeutics, Inc.
Board Appoints James G. Cullem, J.D., to Interim Chief Executive Officer,Joan Y. Brown, CPA, to Interim Chief Financial Officer Press release Cambridge, MA, U.S.A. (June 29, 2022) — Allarity...
Allarity Therapeutics Strengthens Scientific Advisory Board with Appointment of Distinguished Oncologist Roberto Pili, M.D.
15 juin 2022 09h25 HE
|
Allarity Therapeutics, Inc.
Cambridge, MA U.S.A. (June 15, 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with...
Allarity Therapeutics Reports First Quarter 2022 Financial Results
27 mai 2022 17h37 HE
|
Allarity Therapeutics, Inc.
Cambridge, MA U.S.A. (May 27, 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with...
Correction Notice to Press Release Announcing Financial Results For the Fourth Quarter and Full Year 2021 Financial Results and Corporate Update
18 mai 2022 17h30 HE
|
Allarity Therapeutics, Inc.
Cambridge, MA U.S.A. (May 18, 2022) — Allarity Therapeutics, Inc. (NASDAQ: ALLR) announced today that its press release issued under the headline “Allarity Therapeutics Reports Fourth Quarter and Full...
Allarity Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update
16 mai 2022 19h40 HE
|
Allarity Therapeutics, Inc.
Cambridge, MA U.S.A. (May 16, 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with...
Allarity Therapeutics Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1)
22 avr. 2022 17h00 HE
|
Allarity Therapeutics, Inc.
Cambridge, MA U.S.A. (April 22, 2022) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics...
Allarity Therapeutics Provides Update on Dovitinib Program
15 mars 2022 08h32 HE
|
Allarity Therapeutics, Inc.
FOR IMMEDIATE RELEASE Allarity has requested a Type C meeting with the FDA to discuss potential clinical paths to support approval of dovitinib in view of the regulatory agency’s recent Refusal to...
Allarity Therapeutics Receives Refusal to File Letters from U.S. FDA
18 févr. 2022 16h15 HE
|
Allarity Therapeutics, Inc.
Refusal to File letters concern the new drug application for dovitinib and the DRP®-Dovitinib companion diagnostic pre-market approval applicationAllarity intends to seek guidance from the FDA on...
Allarity Therapeutics and Oncoheroes Biosciences Sign Agreements to Advance Pediatric Cancer Development of Dovitinib and Stenoparib
03 janv. 2022 08h00 HE
|
Allarity Therapeutics, Inc.
Press release Oncoheroes will fund and advance the clinical development of both dovitinib and stenoparib in pediatric cancers, utilizing Allarity’s DRP® companion diagnostics Allarity...
Allarity Therapeutics Submits New Drug Application (NDA) to the U.S. FDA for Dovitinib for Third-Line Treatment of Renal Cell Carcinoma (RCC)
22 déc. 2021 08h00 HE
|
Allarity Therapeutics, Inc.
Marks Allarity’s first regulatory application for marketing approval for one of its prioritized oncology pipeline programs NDA is supported by Allarity’s previously-filed pre-market approval (PMA)...